Combined analysis of gut microbiome and serum metabolomics reveals novel biomarkers in patients with early-stage non-small cell lung cancer

• DOI: 10.3389/fcimb.2023.1091825
• Publication Date: 2023-01-20T06:19:16Z
• Authors: Boxiong Ni; Xianglong Kong; Yubo Yan; Bicheng Fu; Fucheng Zhou; Shidong Xu
• Keywords: Sphingolipid; Eicosanoid metabolism; Metabolome

Non-small cell lung cancer (NSCLC) is the predominant form of and one most fatal cancers worldwide. Recently, International Association for Study Lung Cancer (IASLC) proposed a novel grading system based on high-grade histological patterns invasive pulmonary adenocarcinoma (IPA). To improve outcomes NSCLC patients, we combined serum metabolomics fecal microbiology to screen biomarkers in patients with early-stage identified characteristic microbial profiles different grades IPA. 26 genera 123 metabolites were significantly altered patients. Agathobacter, Blautia, Clostridium, Muribaculacea more abundant compared healthy controls. For IPA, microorganisms are as follows: Blautia Marinobacter IPA grade type 1; Dorea 2; Agathobacter 3. In metabolome results, group mainly included higher levels sphingolipids (D-erythro-sphingosine 1-phosphate, palmitoyl sphingomyelin), fatty acyl (Avocadyne 1-acetate, 12(S)-HETE, 20-Carboxy-Leukotriene B4, Thromboxane B3, 6-Keto-prostaglandin f1alpha, Sebacic acid, Tetradecanedioic acid) glycerophospholipids (LPC 20:2, LPC 18:0, 18:4, LPE 20:1, 16:1, 20:0, LPA 18:2, 17:1, 17:2, 19:0). Dysregulation pathways, such sphingolipid metabolism signaling pathway may become an emerging therapeutic strategy early-NSCLC. Correlation analysis showed that gut microbiota metabolic closely related, while Clostridium core genera. These findings provide new diagnosis precise assessment prognostic-related IPAs, which clinical importance warrant further investigation underlying molecular mechanisms.